Just Published: Imaging update in inflammatory arthritis

Just Published: Imaging update in inflammatory arthritis

Imaging update in inflammatory arthritis.

A new article ‘Imaging update in inflammatory arthritis‘ co-authored by our collaborators Iwona Sudoł-Szopinska, Chiara Giraudo, Edwin H.G. Oei, and Lennart Jans was published in Elsevier’s Journal of Clinical Orthopaedics and Trauma, June 2021.

Book: Imaging update in inflammatory arthritis

Access Online: here

Published: June 2021

A b s t r a c t
Ultrasonography and magnetic resonance imaging have become important imaging modalities in rheumatological disorders next to standard radiography.

Due to their ability to assess both morphological and functional changes they play a significant role in early diagnosis and treatment monitoring.

This review presents the latest advancements in imaging of inflammatory arthritis with a focus on two main groups of rheumatic diseases: connective tissue diseases and spondyloarthritis.

New developments related to peripheral and sacroiliac joints imaging are discussed, including Superb Micro Flow Imaging and Shear Wave Elastography in ultrasonography, as well as Whole Body MRI, quantitative MRI, and the recent advances in cartilage imaging in MRI, including T2-and T1p-mapping, and dGEMRIC. The role of emerging imaging techniques in the early diagnosis of inflammatory arthritis is discussed, including DECT, VIBE, BoneMRI, and pQCT.

About IAG, Image Analysis Group

Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes.

Reach out to our expert team to discuss your development programs: imaging.experts@ia-grp.com